Discuss cutting-edge topics with CGT experts during ASGCT's Insights Week! Choose from five daily sessions between Oct. 16-20
The Gene, Cell, & RNA Therapy Landscape report, created in partnership with Informa Pharma Intelligence, is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.
In Q2 2023:
Six therapies were approved, including two gene therapies, Elevidys and Vyjuvek, that were the first to be approved for their respective indications
Roctavian was approved in the U.S.
More gene therapies moved into Phase II trials in the past quarter than have in more than a year
Read the Full Report
Read all the landscape reports from 2023.
Read all the landscape reports from 2022.
Read all the reports from 2021 here.
Watch on demand through Oct. 23!
© 2000-2023 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico